This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NeoProfen

Recordati SpA

Drug Names(s): ibuprofen lysine

Description: NeoProfen is a clear sterile preservative-free solution of the L-lysine salt of (±)-ibuprofen which is the active ingredient. (±)-Ibuprofen is a nonsteroidal antiinflammatory agent (NSAID). NeoProfen is designated chemically as a-methyl-4-(2-methyl propyl) benzeneacetic acid lysine salt.

Deal Structure: Lundbeck and Recordati
In December 2012, Lundbeck announced that the company has entered into an asset purchase agreement with Recordati that will acquire a portfolio of Lundbeck's non-core products primarily related to the United States. As part of this transaction, Recordati has acquired rights to the following products: Chemet (succimer), Cosmegen (dactinomycin for injection), Desoxyn (methamphetamine hydrochloride), Elspar (asparaginase), Indocin (indomethacin), Mustargen (mechlorethamine HCL for injection), NeoProfen (ibuprofen lysine), Panhematin (hemin), Peganone (ethotoin) and Tranxene (clorazepate).

Under the terms of the agreement, Recordati has acquired and retains all of Lundbeck's rights and responsibilities for the manufacturing, distribution and sale of the products. The transaction is expected to close at the beginning of 2013 following the applicable antitrust waiting period. The initial payment of USD 80 million will be made at closing in the...See full deal structure in Biomedtracker


NeoProfen News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug